

**Comparative neuropharmacology of the substituted amphetamines,
p-methoxyamphetamine (PMA) &
3,4-methylenedioxymethamphetamine (MDMA)**

Paul Damian Callaghan B.Sc.(Hons.)

Discipline of Pharmacology

School of Medicine

Faculty of Health Sciences

The University of Adelaide

August, 2008

A thesis submitted for the degree of Doctor of Philosophy

Table of Contents

ABSTRACT	I
DECLARATION	III
STATEMENT OF AUTHORSHIP AND CONTRIBUTION	IV
ACKNOWLEDGEMENTS	XI
AUXILIARY PUBLICATIONS NOT FOR ASSESSMENT FOR THIS THESIS	XIII
ABBREVIATIONS, PREFIXES AND SYMBOLS	XIV
1. RESEARCH BACKGROUND	1
1.1. PREVALENCE OF USE (AUSTRALIA AND WORLDWIDE)	2
1.2. HISTORICAL ORIGINS OF PMA AND MDMA	7
1.3. ACUTE CLINICAL PHARMACOLOGY	8
1.3.1. <i>Mood state</i>	8
1.3.2. <i>Body temperature</i>	9
1.3.3. <i>Stimulant effects (activity/cardiovascular)</i>	10
1.4. MECHANISM OF ACTION	11
1.4.1. <i>Serotonergic neurotransmission</i>	14
1.4.2. <i>Dopaminergic neurotransmission</i>	18
1.4.3. <i>Noradrenergic neurotransmission</i>	21
1.4.4. <i>Direct receptor interactions</i>	22
1.5. PHYSIOLOGICAL/BEHAVIOURAL EFFECTS IN ANIMALS	23
1.5.1. <i>Thermoregulation</i>	23
1.5.2. <i>Serotonin syndrome and stimulant effects</i>	25
1.5.3. <i>Cardiovascular effects</i>	26
1.6. PHARMACOKINETICS	26
1.7. METABOLISM.....	27
1.8. LONG TERM RESIDUAL EFFECTS	32
1.8.1. <i>Long term alterations in monoamine and indolamine content in the CNS</i>	35

1.8.2.	<i>Axonal degeneration</i>	39
1.8.3.	<i>Evidence against serotonergic neurotoxicity after MDMA administration</i>	41
1.8.4.	<i>Potential mechanisms for substituted amphetamine-mediated neurodegeneration</i>	42
1.8.5.	<i>Physiological/behavioural effects after prior substituted amphetamine administration in animal models</i>	47
1.8.6.	<i>Repeated MDMA use in humans: Clinical studies</i>	48
1.9.	RESEARCH AIMS:	51
1.9.1.	<i>Project aims</i>	52
1.9.2.	<i>Publication 1: “Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat”</i>	52
1.9.3.	<i>Publication 2: “Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry”</i>	53
1.9.4.	<i>Publication 3: “Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxy-methamphetamine”</i>	54
1.9.5.	<i>Publication 4: “In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA) but not 3,4-methylenedioxymethamphetamine (MDMA) leads to long lasting deficits in serotonin transporter function”</i>	55
2.	PUBLICATION 1	56
3.	PUBLICATION 2	81
4.	PUBLICATION 3	95
5.	PUBLICATION 4	104
6.	DISCUSSION AND CONCLUSIONS	117
	BIBLIOGRAPHY	140

List of Figures

FIGURE 1: PREVALENCE OF AMPHETAMINE TYPE SUBSTANCES ON A COUNTRY BY COUNTRY BASIS.....	4
FIGURE 2: PERCEIVED HARMFULNESS OF ECSTASY DOES NOT CORRELATE WITH OCCURRENCE OF ACUTE ADVERSE EVENT, AS MEASURED BY EMERGENCY ROOM ADMISSIONS.....	5
FIGURE 3: CLANDESTINE MANUFACTURE OF ECSTASY	5
FIGURE 4: PREVALENCE OF ECSTASY USE IN AUSTRALIA, 1988-2004	6
FIGURE 5: MECHANISM OF ACTION OF MDMA FINISH	12
FIGURE 6: METABOLISM OF MDMA	29
FIGURE 7: METABOLISM OF PMA	30

Abstract

Dramatic growth in substituted amphetamines ('Ecstasy') use since the 1980's has correlated with increased incidence of acute toxicity and residual neuropsychological deficits. This thesis aimed to characterise the acute neurochemical mechanisms and residual neurochemical alterations produced by p-methoxyamphetamine (PMA), which is usually sold as 'ecstasy' and is associated with greater acute toxicity than 3,4-methylenedioxymethamphetamine (MDMA). While both PMA and MDMA primarily modulate dopaminergic and serotonergic neurotransmission, little is known of the differences in the neurochemical effects of PMA within the central nervous system, *in vivo*. This thesis used *in vivo* chronoamperometry to elucidate the acute neurochemical alterations in monoaminergic pharmacology *in vivo* after local application of PMA or MDMA within discrete brain nuclei in anaesthetised rats. Measurement of evoked release of monoamines including serotonin (5-HT), and inhibition of neurotransmitter uptake via membrane transporters were assessed.

Initial studies compared pharmacodynamic responses of PMA and MDMA, showing PMA to have greater efficacy and potency for alteration of core body temperature in rats, a primary cause of acute toxicity, within minimal alteration in locomotion. Dose-response studies indicated local PMA application within striatum resulted in significantly greater 5-HT evoked release than MDMA, yet lesser dopaminergic release, as predicted by the pharmacodynamic data. Only PMA-evoked release could be partially blocked by pre-treatment with a 5-HT reuptake inhibitor (SERT). Differences in both the qualitative and quantitative nature of striatal evoked-release of 5HT and dopamine were noted for both drugs, which had not been previously seen. Both PMA and MDMA inhibited 5-HT clearance, but only MDMA inhibited dopamine clearance in striatum. Dose-response studies in the CA3 region of hippocampus indicated PMA was also more efficacious than MDMA in the inhibition of 5-HT clearance *in vivo*.

While the question of whether long term MDMA use induces selective neurodegeneration (reductions in serotonergic *in vitro* biomarkers) is still unclear, it was not known for PMA prior to this work. Repeated PMA administration was shown to result in reductions in cortical SERT (indicative of potential loss of 5-HT terminal axons), cortical 5-HT content was unaltered. A subsequent comprehensive study followed, comparing the residual effects of PMA or MDMA

administration on *in vitro* serotonergic biomarkers (markers of selective neurodegeneration) and SERT function *in vivo*. PMA administration resulted in reductions in hippocampal SERT binding and [³H]-5HT synaptosomal uptake, correlating with *in vitro* biomarkers previously used. SERT function *in vivo* using chronoamperometric techniques was reduced, as would be predicted. However, hippocampal 5-HT content was again not reduced, indicating that selective neurodegeneration of 5-HT fibres may not in fact be occurring. MDMA administration reduced all measured *in vitro* serotonergic biomarkers, however SERT function *in vivo* was completely unaltered. These data indicate that reductions of *in vitro* biomarkers of 5-HT axonal degeneration do not necessarily predict the potential compensatory mechanisms that maintain SERT function *in vivo*. Compensatory mechanisms appear to exist *in vivo* to maintain clearance of extracellular 5-HT that may be disrupted or eliminated during tissue preparation for *in vitro* assays.

In summary, while PMA produced significantly greater alterations, compared to MDMA, in processes intrinsic to 5-HT neurotransmission in both striatum and hippocampus, the magnitude of these responses did not explain the significantly higher risk of acute toxicity seen clinically with PMA use. The second component of the thesis extended beyond prior work, investigating the potential neurodegenerative effects of PMA and MDMA through the assessment of changes in *key functional processes* in 5-HT neurotransmission. It is hoped this will contribute to the subsequent characterisation of the mechanism(s) of functional compensation in 5-HT neurotransmission which may lead to more targeted treatments to modulate potential psychological/psychiatric deficits that occur in regular 'ecstasy' users.

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed below) resides with the copyright holder(s) of those works.

Daws L. C., Irvine R. J., **Callaghan P. D.**, Toop N. P., White J. M. and Bochner F. (2000) Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. *Prog Neuropsychopharmacol Biol Psychiatry* 24, 955-977.

Callaghan P. D., Irvine R. J. and Daws L. C. (2005) Differences in the *in vivo* dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. *Neurochem Int* 47, 350-361.

Callaghan P. D., Farrand K., Salem A., Hughes P., Daws L. C. and Irvine R. J. (2006) Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxymethamphetamine. *Eur J Pharmacol* 546, 74-81.

Callaghan P. D., Owens W. A., Javors M. A., Sanchez T. A., Jones D. J., Irvine R. J. and Daws L. C. (2007) *In vivo* analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. *J Neurochem* 100, 617-627.

Paul Damian Callaghan, 25/8/08

Statement of Authorship and Contribution

Publication 1:

Daws L. C., Irvine R. J., **Callaghan P. D.**, Toop N. P., White J. M. and Bochner F. (2000) Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. *Prog Neuropsychopharmacol Biol Psychiatry* 24, 955-977.

Impact factor: 2.584 (2006)

Author Contribution:

Mr Callaghan had a major input in the experimental design, conducted all *in vivo* electrochemical experimental procedures, statistical analysis and graphical presentation of the data collected, and was involved in preparation of the manuscript for submission.

Miss Toop was involved in the experimental design, conducted telemetric studies and contributed to the interpretation of the data collected, and preparation of the manuscript.

Professor Bochner was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript.

Professor White was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript.

Associate Professor Irvine was involved in the experimental design, conducted telemetric studies and contributed to the interpretation of the data collected and preparation of the manuscript.

Associate Professor Daws was involved in the experimental design, contributed to the interpretation of the data collected and preparation of the manuscript

NOTE:

Statements of authorship appear in the print copy of the thesis held in the University of Adelaide Library.

Publication 2:

Callaghan P. D., Irvine R. J. and Daws L. C. (2005) Differences in the *in vivo* dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. *Neurochem Int* 47, 350-361.

Impact factor: 3.159 (2006)

Author Contribution:

Mr Callaghan had a major input in the experimental design, conducted all experimental procedures, statistical analysis and graphical presentation of the data collected, and prepared the manuscript for submission.

Associate Professor Irvine was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript.

Associate Professor Daws was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript

NOTE:

Statements of authorship appear in the print copy of the thesis held in the University of Adelaide Library.

Publication 3:

Callaghan P. D., Farrand K., Salem A., Hughes P., Daws L. C. and Irvine R. J. (2006)
Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxymethamphetamine. *Eur J Pharmacol* 546, 74-81.

Impact factor: 2.522 (2006)

Author Contribution:

Mr. Callaghan had a major input in the experimental design, conducted all HPLC analysis for experiment 2, conducted all statistical analysis and graphical presentation of the data collected, and prepared the manuscript for submission.

Dr. Farrand was involved in the experimental design, conducted experimental procedures for experiment 1, and interpretation of the data collected.

Mr. Hughes was involved in the experimental design and conducted animal procedures for experiment 2.

Dr. Salem was involved in the experimental design, contributed to the experimental procedures, interpretation of the data collected and preparation of the manuscript.

Associate Professor Irvine was involved in the experimental design, contributed to the experimental procedures, interpretation of the data collected and preparation of the manuscript.

Associate Professor Daws was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript.

NOTE:

Statements of authorship appear in the print copy of the thesis held in the University of Adelaide Library.

Publication 4:

Callaghan P. D., Owens W. A., Javors M. A., Sanchez T. A., Jones D. J., Irvine R. J. and Daws L. C. (2007) *In vivo* analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. *J Neurochem* 100, 617-627.

Impact factor: 4.260 (2006)

Author Contribution:

Mr Callaghan had a major input in the experimental design, conducted all animal procedures, *in vivo* electrochemical procedures, autoradiography procedures, preparation of samples for HPLC analysis, conducted all statistical analysis and graphical presentation of the data collected, and prepared the manuscript for submission.

Mr. Owens was involved in the autoradiographic procedures, and interpretation of the data collected.

Ms. Sanchez conducted *in vitro* hippocampal 5-HT and noradrenaline uptake procedures, and interpretation of the data collected.

Professor Jones was involved in the experimental design of *in vitro* hippocampal 5-HT and noradrenaline uptake procedures, contributed to the experimental procedures and interpretation of the data collected.

Professor Javors was involved in conducting HPLC analysis of extracted 5-HT samples, and interpretation of the data collected.

Associate Professor Irvine was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript.

Associate Professor Daws was involved in the experimental design, and contributed to the interpretation of the data collected and preparation of the manuscript.

NOTE:

Statements of authorship appear in the print copy of the thesis held in the University of Adelaide Library.

Acknowledgements

There are so many people to thank for this long odyssey (I had hair when I started, there's even a picture to prove it!) that has been my PhD. Covering two continents, it has been an amazing experience, I am so grateful to you all! There is not enough space to do everyone justice, but you are not forgotten!

I wish to especially thank all the members of the Department of Pharmacology at the University of Adelaide, past and present. Your support has made this all possible. I wish to especially thank Prof. Felix Bochner and Prof. Jason White for my time in the department. Many thanks go to all my fellow students, especially to Ben Phillis, Tanya Lewanowitsch and Ray Chan, for advice, help and assorted adventures! In particular, I'm very grateful to Gordon Crabb, Cathy Smith and Karen Nunes-Vas, for making so many things possible over my time, keeping everything running smoothly. I am also greatly indebted to Dr. Abdallah Salem, for your advice, training and help with HPLC.

There are so many people to thank for support, advice and for making my time at University of Texas Health Science Center at San Antonio so memorable. I wish to especially thank Prof. Alan Frazer, for your acceptance of me into your laboratory, and insightful ideas, comments and suggestions. Also I am so grateful to all staff and students in the lab through my tenure, especially Georgianna Gould and Saloua Benmansour, who helped me so much in adapting to living in a new place, and country! Also many thanks to Cathy Franks, Sandra Westerman, Marlys and Lucy, you looked after me on many an occasion and your support was invaluable. I am also indebted to Dr. Aureilo Galli, for scientific advice, collaboration and entertainment! Mei Lim, Kris Kahlig, Bonnie Garcia, Nicole Sullivan, Habibeh Khoubeui, Hongwei Wang, Gene Castro, Eva and Michael Guetterez & Eva Loh, thanks for your time, advice, friendship and adventures!

Many special thanks especially to my fellow lab members at UTHSCSA, especially Anthony Owens and Sylvia Montañez (and honorary member, David McLoughlin) for

your help, advice and adventures. I couldn't have done it without you! So many fond memories! The good (Sylvia's mums tacos), the bad (Via buses & fire ants) and the ugly (China star restaurant)! No one since has matched the quality of our late night lab entertainment!

I also wish to thank Prof. David Jones, Prof. Marty Javor and Teresa Sanchez for your collaboration that made the last study so complete.

To my supervisors, Lyn Daws and Rod Irvine, I am so grateful for your faith in me, guidance and support along this journey. Your encouragement and generosity of time will not be forgotten, it has been such a high point in my career thus far. I cannot thank you both enough.

Last, but not least, to my family, to my mum and dad, who encouraged my interest in education and science, and who have taught me so much, without which this would have been impossible. There is so much more to say, that is hard to express in words. Dad, without your support along the way, in so many different forms, this could not have happened. To my brothers, Brian and Leo, and my uncle, John, you all made this possible, and I am indebted to you all for your support on so many levels.

Auxiliary publications not for assessment for this thesis

The following publications would be presented as auxiliary publications, indicating my current research contribution to the field of the pharmacology of stimulants and drug abuse. These publications will not be presented for assessment for the degree of Doctor of Philosophy.

Kaminskas L.M., Irvine R.J., Callaghan P.D., White J.M. and Kirkbride P. 2002. The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine. *Psychopharmacology (Berl)* 160, 155-160. Impact factor: 3.625 (2006)

Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A. and Galli A. 2002. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. *Biochem Biophys Res Commun* 290, 1545-1550. Impact factor: 2.855 (2006)

Irvine, R.J., Keane, M., Felgate. P., McCann, U.D., Callaghan, P.D., White, J.M. 2005. Plasma Drug Concentrations and Physiological Measures in 'Dance Party' Participants. *Neuropsychopharmacology*. 31(2), 424-30. Impact factor: 5.889 (2006)

Abbreviations, prefixes and symbols

PMA	p-methoxyamphetamine
MDMA	3,4-methylenedioxyamphetamine
CNS	Central nervous system
POHA	p-hydroxyamphetamine
5-HT	5-hydroxytryptamine
5-HIAA	5-hydroxy-indolacetic acid
MAO	Monoamine oxidase
SERT	5-HT transport protein
DAT	Dopamine transport protein
IC ₅₀	Concentration of 50% inhibitory response
EC ₅₀	Concentration of 50% response
E _{max}	Maximal response
MTA	Myoclonic twitch activity
PKC	Protein kinase C
NET	Noradrenaline transporter protein
KO	Knockout
GABA	gamma-hydroxybutyric acid
LD ₅₀	Dose resulting in 50% lethality
CYP	Cytochrome P450 isozyme
MDA	Methylenedioxyamphetamine
HHMA	Dihydroxymethamphetamine
HHA	Dihydroxyamphetamine
OHMDMA	6-hydroxymethylenedioxyamphetamine
THMA	2,4,5-trihoxymethamphetamine
COMT	catechol-O-methyl transferase

MMAI	5-methoxy-6-methyl-2-aminoindan
BID	Twice daily
GFAP	Glial acidic fibrillary protein
PBR	Peripheral benzodiazepine receptor
kDa	Kilodalton
NO	Nitric oxide
nNOS	neural nitric oxide synthase
L-DOPA	L-3,4-dihydroxyphenylalanine
m-CPP	m-chlorophenylpiperazine
CSF	Cerebrospinal fluid
PET	Positron emission tomography
SPECT	Single photon emission computed tomography
OCT	Organic cation transporter
mRNA	Messenger ribonucleic acid

*And the world's concerns with its rights and wrongs
Shall seem but small things
Poet or painter, a singer of songs,
Thine art is all things.*

*For the wine of life is a woman's love
To keep beside thee
But the love of Art is a thing above
A star to guide thee.*

*As the years go by with thy love of Art
All undiminished
Thou shalt end thy days with a quiet heart
Thy work is finished.*

Passage from 'Ambition and Art', by A.B. 'Banjo' Patterson